scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant (USA)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant from Pfizer supports researchers in the USA working on ATTR Amyloidosis. Applicants must be based at a research institution and must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.

The grant seeks to fund projects on:

  • Approaches for the early identification and follow up of ATTR amyloidosis patients
  • Real-world (RW) efficacy and safety of tafamidis in the clinical setting for the management of
  • ATTR amyloidosis
  • Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy
  • and polyneuropathy)
  • Gender/sex-related differentiation
  • Pathophysiology

Applicants may apply for up to 75,000 USD/year in funding support (including up to 28% of overheads) for 1-2 years.

Applications close on April 27, 2023.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time

Be the first to know

Sign-up for Personalized Grant Alerts

Logo3